Dermata Therapeutics Inc (DRMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,945 | 7,522 | 4,664 | 6,481 | 9,719 |
| Inventories | 93 | N/A | N/A | N/A | N/A |
| TOTAL | $7,466 | $7,864 | $5,071 | $6,641 | $10,005 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $7,466 | $7,864 | $5,071 | $6,641 | $10,005 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 318 | 461 | 453 | 414 | 1,395 |
| Accrued Expenses | 734 | 1,180 | 658 | 613 | 1,309 |
| TOTAL | $1,053 | $1,640 | $1,111 | $1,026 | $2,704 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $1,053 | $1,640 | $1,111 | $1,026 | $2,704 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 4,022 | 4,022 | 1,026 | 682 | 638 |
| Common Shares | 0 | 0 | 0 | 0 | 1 |
| Retained earnings | -75,082 | -73,234 | -71,372 | -69,680 | -67,979 |
| TOTAL | $6,413 | $6,223 | $3,960 | $5,614 | $7,301 |
| Total Liabilities And Equity | $7,466 | $7,864 | $5,071 | $6,641 | $10,005 |